Vaccine Adjuvant
CpG ODNs are better than Resiquimod as vaccine adjuvants
Published in Vaccine Weekly, January 4th, 2006
According to a report from Canada, "TLR ligands that mimic pathogen associated molecular pat terns and activate immune cells via Toll-like receptors (TLRs) are being developed for use in humans as therapy against a variety of diseases as well as vaccine adjuvants. These include imidazoquinoline compounds such as imiquimod and resiquimod (R-848) that bind to TLR7 and 8, as well as CpG oligodeoxynucleotides (CpG ODNs) that bind to TLR9."
"This study compared CpG ODNs and R-848 for their potential use as vaccine adjuvants and to determined whether there are additive or...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2006-01-04)
More Articles from Vaccine Weekly
- Cervical Cancer
Pharma company submits biologics license application for papillomavirus vaccine to U.S. FDA - Chickenpox Vaccine
Varicella vaccination in Australia is the focus of review - Escherichia Coli Vaccine
Live diarrheal vaccine imprints Th2 cell bias and is anti-inflammatory - SARS Vaccine
Inactivated virus immunization modulates immune response to SARS spike glycoprotein - Adenovirus Vector
Oncolytic adenovirus replicates selectively in tumors - Allergy & Immunology
Mycobacteria exposure primes immune system for evolutionarily diverse heat shock proteins - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
